



Fractional CO₂ Laser Versus Microneedling Combined with Narrowband Ultraviolet and Topical Steroid for Treating Non-Segmental Vitiligo in Treatment-Resistant Localizations: A Comparative Randomized Clinical Trial Study

Parvin Mansouri¹, Mohammadreza Rahbar^{1*}, Mohammad Ali Nilforoushzadeh¹, Mohsen Shati²,
Mohammad Amir Amirkhani¹

¹Skin and Stem Cell Research Center, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

²Mental Health Research Center, Social Injury Prevention Research Institute, Iran University of Medical Sciences, Tehran, Iran

***Correspondence to**

Mohammadreza Rahbar,
Email: mrzrahbar@yahoo.com

Received: February 21, 2024

Accepted: June 1, 2024

ePublished: August 10, 2024

Abstract

Introduction: Vitiligo poses a significant challenge, particularly in treatment-resistant areas such as acral regions. This study aimed to evaluate the effectiveness and safety of combining fractional CO₂ laser and microneedling with conventional therapies for non-segmental vitiligo in resistant areas.

Methods: A randomized clinical trial with a paired design was conducted on 84 individuals with non-segmental vitiligo and treatment-resistant lesions. Participants in two separate groups received various combinations of interventions, including narrowband ultraviolet B (NB-UVB) and topical steroid (Clobetasol ointment) as conventional treatments, with fractional CO₂ laser or microneedling as add-ons for four symmetrical treatment-resistant lesions. The treatment duration was 16 weeks, followed by observation until six months post-intervention for each patient, and it focused on assessing the percentage of repigmentation, safety, patient satisfaction, and potential adverse effects.

Results: The results of the study revealed a significant difference in average efficacy, with treatments involving fractional CO₂ laser and microneedling compared with other interventions without them showing a higher percentage of repigmentation. No notable distinction in repigmentation patterns was observed, except for slightly higher marginal repigmentation with microneedling. Side effects, including pain, burning sensation, and erythema, were more frequent, with no significant difference between the groups. Itching and crusting had a significant difference in the two groups. Patient satisfaction levels were comparable, with the first group slightly more than the second.

Conclusion: In conclusion, combining NB-UVB and topical steroid therapies with the fractional CO₂ laser or microneedling seems to be effective for vitiligo treatment in resistant areas. Attention to variations in patients' characteristics and specific body locations is necessary when applying these modalities. This study provides valuable insights into novel approaches for managing vitiligo and highlights the potential benefits of these innovative treatments in combination with conventional therapy.

Keywords: Vitiligo; CO₂ laser; Microneedling; Combination therapy.



Introduction

Vitiligo, a common skin condition affecting approximately 0.5% to 2% of the population,¹ causes depigmentation of the skin due to the loss of melanocytes. A survey of one-thousandth of the Iranian population estimated the prevalence of vitiligo at 0.6%.² Another study in Iran found significantly higher levels of anxiety and hopelessness in vitiligo patients compared to healthy individuals.³ Psycho-social comorbidities, which affect

almost 90% of patients with vitiligo, are common, with a societal stigma and an impact on the quality of life.^{4,5}

Lesions in acral regions, such as the hands and feet, and on bony prominences like knees and elbows often do not respond well to conventional treatments.⁶ Research indicates that the face is the most commonly affected area, followed by the acral regions and extremities.⁷ Given the frequent involvement of acral regions, patients with lesions in these areas experience more pronounced

impairment in the quality of life due to visibility and treatment resistance. This highlights the need for psychosocial support alongside medical care.⁸

Various conventional treatments for vitiligo include topical corticosteroids, topical calcineurin inhibitors, phototherapy, laser therapy, and, in specific cases, surgical options. Narrowband ultraviolet B (NB-UVB) phototherapy, used either alone or in combination with other treatment modalities, is recognized as an effective and primary treatment for vitiligo.⁹⁻¹² Topical corticosteroids are commonly used in the treatment of vitiligo and are effective in achieving repigmentation in patients with vitiligo.¹³⁻¹⁵

Combination therapies, including NB-UVB, have shown improved repigmentation in vitiligo compared to single treatments. The use of various agents such as psoralens, corticosteroids, vitamin D analogs, fluorouracil, azathioprine, and oral prednisolone has demonstrated enhanced efficacy in treating vitiligo.¹⁶

In recent years, microneedling and fractional CO₂ lasers have been considered promising adjunctive approaches for vitiligo treatment. Recent studies have explored the fractional CO₂ laser as a supplementary vitiligo treatment, demonstrating its efficacy in repigmentation, particularly on the trunk, when combined with NB-UVB.¹⁷ Additionally, the fractional CO₂ laser, alongside traditional treatments, has shown promise for stubborn vitiligo cases.¹⁸ Microneedling, when integrated with other therapies, enhances outcomes, with studies highlighting its efficacy in addressing vitiligo lesions, especially when combined with topical medications or NB-UVB phototherapy.¹⁹⁻²¹ Microneedling effectiveness in repigmenting vitiligo may result from microinflammation stimulating melanocytes. The fractional CO₂ laser, by stimulating melanogenesis and aiding drug penetration, is a potential add-on therapy for refractory vitiligo lesions, showing promise when combined with standard treatments.²²⁻²⁴ Studies suggest that applying the fractional CO₂ laser before topical drugs improves resistant lesions and accelerates therapy.²³⁻²⁵

Based on the presented evidence, this study aimed to compare and evaluate the efficacy of the fractional CO₂ laser and microneedling as adjunctive combination therapies alongside conventional NB-UVB phototherapy and topical steroid (Clobetasol ointment) treatments for non-segmental vitiligo in treatment-resistant areas. Furthermore, the research sought to assess the safety profiles associated with these two treatment modalities.

Materials and Methods

Study Design

This randomized clinical trial employed a paired (half-body) design to assess the effectiveness and safety of combining NB-UVB and topical steroid (Clobetasol ointment) with the fractional CO₂ laser or microneedling

for repigmentation in vitiligo patches in resistant areas in 84 individuals with non-segmental vitiligo and treatment-resistant lesions on acral areas and bony prominences, who sought treatment at the Skin and Stem Cell Research Centre clinic, Tehran University of Medical Sciences, from 2018 to 2021.

Inclusion and Exclusion Criteria

The study included patients diagnosed with non-segmental (generalized) vitiligo, with each patient having at least two vitiligo lesions, characterized by symmetrical lesions in acral areas and bony prominences of the extremities. All participants were required to be 18 years of age or older.

Individuals classified as skin type 1 with a history of photosensitivity, recurrent skin infections with herpes simplex virus, presence of hypertrophic scars or keloids, and diagnosis of cardiac insufficiency, pregnant or lactating individuals, and patients with inability to comprehend the process, a history of melanoma or non-melanoma skin cancer, and presence of atopic dermatitis and dysplastic nevi were excluded from the study.

All participants who met the inclusion criteria received detailed and complete information about the project process and its aims, and written consent was obtained from all the patients.

Sample Size Calculation

The intricate nested design of the study led us to use PASS software for a conservative sample size determination. Comparable studies reported around 45.9% and 18.4% repigmentation rates in multiple-intervention and control groups, respectively. The software calculated a sample size of 40 for each group, with $P_1=0.459$, $P_2=0.184$, $P=0.275$, $\alpha=0.05$, and $\beta=0.2$. Ultimately, we recruited 42 cases.

Interventions

To examine the efficacy of two modalities, namely fractional CO₂ laser and microneedling, in combination with conventional treatments of topical steroid (Clobetasol ointment) and NB-UVB, we included two groups of participants in the study.

Participants in the first group underwent the following interventions for four treatment-resistant lesions:

- NB-UVB, fractional CO₂ laser, and topical steroid
- NB-UVB and fractional CO₂ laser
- NB-UVB and topical steroid
- NB-UVB alone

In the second group, participants received one of the following treatments for four treatment-resistant lesions:

- NB-UVB, microneedling, and topical steroid
- NB-UVB and microneedling
- NB-UVB and topical steroid
- NB-UVB alone

The treatment duration for both groups lasted 16 weeks. Patients were then observed until the end of 6 months after the start of interventions.

Fractional CO2 Laser Protocol

The fractional CO2 laser treatment in the first group involved two sessions at an 8-week interval, utilizing a fractional CO2 laser device with specific settings (fractional CO2 laser device model: BPX-18A-3376 Italy 10600 nm wavelength). Topical anesthesia cream was applied 45 minutes before the procedure. The depigmented area underwent laser treatment with settings of 100 J pulse energy and a spot density of 150 spots/cm² in static mode.

Microneedling Protocol

In the second group, microneedling was administered for 16 weeks, with 2-week interval sessions totalling 8 sessions using a microneedling device from MT.DERM GmbH, Germany. The depth of microneedling penetration was approximately 1.5 mm to achieve a comparable depth with the fractional CO2 laser treatment, with the desired endpoint of pinpoint bleeding.

Narrowband Ultraviolet B Phototherapy Protocol

Both groups also received NB-UVB phototherapy using the MED light OCTAderm 311 nm narrowband device manufactured in Germany. The NB-UVB treatment commenced four days after each laser or microneedling session, starting with an initial dose of 50 mJ/cm², administered twice weekly over a 4-month period, with a 15% dose increment at each session. Optimal dosing typically manifests as mild pink erythema lasting less than 24 hours.

Steroid Therapy Protocol

Additionally, both groups received topical steroid therapy using Clobetasol ointment, which was applied daily for 2 weeks, followed by a 1-week break, and then repeated for 4 months from the start of the interventions.

Randomization, Blinding, and Concealment

This study employed a single-blind design, with outcome assessors unaware of participants' specific interventions. A coordinator, using randomization tables, allocated participants to either the fractional CO2 laser group or the microneedling group. The coordinator recorded the assigned intervention based on the randomization table, remaining unaware of intervention specifics. Although the nature of interventions could not be concealed, clinic personnel coordinating treatments were informed about the coding system to ensure correct administration.

Data Collection and Outcome Measures

Data collection instruments, including clinical

assessments, questionnaires, imaging, and participant-reported outcomes, focused on changes in pigmentation. The primary outcome was the repigmentation percentage, assessed through standardized digital photographs. Two expert physicians, blinded to the interventions, evaluated these photographs and gave scores to them. The secondary outcomes included safety evaluation, satisfaction, and the pattern of repigmentation. Adverse effects were assessed during and after each session based on patient-reported complaints and the observation of skin responses, including erythema, edema, crust formation, scarring, infection, or other undesired manifestations. Satisfaction was assessed by querying patients about the effectiveness and overall satisfaction with current therapies, specifically addressing novel therapies and inquiring whether patients believe that new and improved vitiligo treatments are effective and necessary.²⁶

The Vitiligo Area Scoring Index (VASI) score was assessed for all patients before the start of the project, and the quality of life was measured by using a valid and reliable Farsi version of the DLQI questionnaire.²⁷

Statistical Methods

Data were analysed with SPSS for Windows 26.0 (IBM Corp Released 2016, NY, USA). Data were described with mean \pm SD and frequency (percent). The normality test was done with the Shapiro-Wilks test. The comparison between the two groups was performed with the independent samples *t* test and Mann-Whitney test, and subgroup comparison was performed with the paired samples *t* test. Pairwise comparison was done with Bonferroni correction for multiple tests. For comparing categorical variables, the chi-square test was applied. The level of significance for all statistical tests was set at $P < 0.05$.

Results

In this study, 84 patients were divided into two equal groups, each comprising 42 patients. Within each group, four types of interventions for treating resistant lesions were compared. The demographic characteristics of patients in each group are shown in Table 1. Findings

Table 1. Demographic and Basic Characteristics of Patients in Each Group

	CO2 Laser Group	Microneedling Group	P Value*
Gender			0.825
Male	17 (40.5%)	18 (42.9%)	
Female	25 (59.5%)	24 (57.1%)	
Age (y)	36.88 \pm 11.56	31.88 \pm 9.38	0.048
The duration of disease (year)	12.98 \pm 7.82	14.83 \pm 9.87	0.533
Percentage of whole body involvement	9.88 \pm 8.77	9.07 \pm 7.72	0.760
VASI score classification	1.36 \pm 0.66	1.36 \pm 0.58	0.673

*P values based on independent *t* test and chi-square test.

showed that the efficacy of NB-UVB treatment on all body areas in the first group was 54.78 ± 8.30 , and in the second group, it was 50.17 ± 13.35 ($P=0.454$). This efficacy did not correlate with the average efficacy of interventions in the subgroups ($P>0.05$).

The research also investigated the correlation between treatment efficacy and demographic variables, including gender, age, disease duration, extent of body involvement, stress, positive family history, and quality of life. The findings from both groups undergoing combination therapies revealed no statistically significant associations with these variables.

The comparison of the efficacy of employing four types of interventions in two modalities is shown in Table 2. In each group, the efficacy was significantly different for each subgroup. In the first group, the post hoc comparison showed that the efficacy of the fractional CO2 laser, NB-UVB, and topical steroid subgroup and the fractional CO2 laser and NB-UVB subgroup had a significant difference with the NB-UVB and topical steroid treatment and also with NB-UVB alone. In the second group, the triple combination subgroup (microneedling, NB-UVB, and topical steroid) and the microneedling, NB-UVB

subgroup had a significant difference with the NB-UVB and topical steroid treatment and also with NB-UVB alone.

Based on what was mentioned above, the combination of NB-UVB, microneedling, and topical steroid achieves the highest efficacy with an average of 20.28% repigmentation, followed by the combination of NB-UVB, fractional CO2 Laser, and topical steroid with an average efficacy of 19.50%. NB-UVB plus microneedling (17.76%) and NB-UVB plus fractional CO2 Laser (16.76%) have the next highest scores. The remaining four interventions, lacking fractional CO2 or microneedling as additional interventions, exhibit lower scores with greater differences than the first-mentioned subgroups. These rankings underscore the diverse levels of efficacy across different treatment approaches (Figure 1).

Comparison of the Repigmentation Pattern

In this investigation, we explored the repigmentation pattern in two groups undergoing triple combination treatments. The findings are detailed in Table 3. According to the chi-square test results, there is no significant distinction between the two groups across

Table 2. Comparison of the Efficacy of Treatment Between and Within Subgroups

1 st Group	Subgroup				P Value*
	Fractional CO2 Laser, NB-UVB, and Topical Steroid	Fractional CO2 Laser and NB-UVB	NB-UVB and Topical Steroid	NB-UVB alone	
Fractional CO2 Laser	19.5 ± 7.98	16.76 ± 6.07	9.76 ± 7.66	7.69 ± 5.63	0.0001
2 nd Group	Microneedling, NB-UVB, and Topical Steroid	Microneedling and NB-UVB	NB-UVB and Topical Steroid	NB-UVB Alone	P Value*
Microneedling	20.29 ± 6.16	17.76 ± 5.54	9.62 ± 4.57	8.48 ± 4.23	

*P values based on ANOVA test.




Figure 1. Average Percentage of Efficacy Scores by Group

the four repigmentation pattern categories at a 95% confidence level ($P > 0.05$). However, by reducing the confidence level to 90%, it can be asserted that a difference exists between the two groups concerning marginal repigmentation, with a 10% error level ($P < 0.1$). The proportion of repigmentation in the second group, where microneedling was applied, surpasses that in the first group.

Side Effects

In Table 4, the frequency of adverse side effects in each group was compared. Specifically, significant variations were observed in itching and crusting. It is noteworthy that no significant distinctions were observed in other adverse effects between the two groups.

Patient Satisfaction

Satisfaction levels were 1.47 ± 1.04 in the first group and 1.26 ± 1.06 in the second group ($P = 0.362$).

Based on the results obtained from the analysis of variance, it is indicated that the level of satisfaction did not have a significant difference between the two groups at a 95% confidence level ($P > 0.05$). However, descriptively, group 1 exhibited a more favorable satisfaction level compared to group 2.

Discussion

The study conducted a randomized clinical trial using a paired design to investigate the efficacy and safety of combining NB-UVB and topical steroid with the fractional CO₂ Laser or microneedling for repigmentation in vitiligo patches in treatment-resistant areas. The analysis of demographic data revealed a slight variation in gender distribution between the two groups, with the chi-square test indicating no statistically significant difference. This balanced gender distribution minimizes potential biases in treatment outcomes based on gender.

In reference to vitiligo, there were some interesting

Table 3. Comparison of the Repigmentation Pattern in Two Groups

Pattern of Repigmentation	Result	Group		P Value*
		1 st Group - CO ₂ Fractional, NB-UVB and Topical Steroid	2 nd Group - Microneedling, NB-UVB and Topical Steroid	
Diffuse repigmentation	No	11 (26%)	14 (33%)	0.474
	Yes	31 (74%)	28 (67%)	
Marginal repigmentation	No	30 (71%)	22 (52%)	0.072
	Yes	12 (29%)	20 (48%)	
Perifollicular repigmentation	No	30 (71%)	31 (74%)	0.807
	Yes	12 (29%)	11 (26%)	
Combined repigmentation	No	24 (57%)	23 (55%)	0.826
	Yes	18 (43%)	19 (45%)	

*P values based on chi-square test.

Table 4. Comparison of the Frequency of Side Effects Between Two Groups

Side Effects	Result	Group		P Value*
		1 st Group - CO ₂ Fractional, NB-UVB and Topical Steroid	2 nd Group - Microneedling, NB-UVB and Topical Steroid	
Pain	No	1 (2%)	2 (5%)	0.557
	Yes	41 (98%)	40 (95%)	
Burning sensation	No	1 (2%)	2 (5%)	0.557
	Yes	41 (98%)	40 (95%)	
Erythema	No	5 (12%)	7 (17%)	0.533
	Yes	37 (88%)	35 (83%)	
Itching	No	15 (36%)	24 (57%)	0.049
	Yes	27 (64%)	18 (43%)	
Crusting	No	20 (48%)	30 (71%)	0.026
	Yes	22 (52%)	12 (29%)	
Scarring	Yes	0 (0%)	0 (0%)	-
Infection	Yes	0 (0%)	0 (0%)	-
Köbner phenomenon	Yes	0 (0%)	0 (0%)	-

*P values based on chi-square test.

results with regard to how the safety and efficacy of various kinds of treatment were combined in the study. The results of this study show that the combination of NB-UVB, microneedling, and topical steroid is the kind of combination which has the highest efficacy in terms of repigmentation, averaging 20.28%. This combination outperformed other treatment modalities, including NB-UVB with the fractional CO₂ Laser and NB-UVB with microneedling, showcasing its potential as a promising therapeutic approach for vitiligo in treatment-resistant areas.

Further analysis within subgroup comparisons indicated that the triple combination therapy subgroup in both groups showed a significantly higher efficacy compared to the two combination treatment subgroup. This comparison between subgroups suggests that the addition of microneedling to the treatment regimen may enhance the overall repigmentation outcomes in vitiligo patients with treatment-resistant lesions. Microneedling and fractional CO₂ laser were found to enhance the efficacy of vitiligo treatment when used as add-ons, with microneedling noted for inducing collagen, elastin, and growth factors, facilitating melanocyte migration and showing positive outcomes in refractory cases. In addition, fractional CO₂ laser treatments, especially in combination with other therapies like PRP and betamethasone, demonstrated significant improvements in refractory vitiligo cases, particularly in acral areas.²¹

Microneedling and fractional CO₂ laser emerged as promising treatments for resistant vitiligo cases, with studies supporting their effectiveness in stimulating epidermal alterations and facilitating melanocyte migration ($P < 0.01$).²¹ These treatments have shown positive pigmentation outcomes in stable, localized, refractory vitiligo cases.²⁸

The study findings, supported by references, highlight significant achievements in vitiligo research. The study revealed a balanced gender distribution, minimizing gender-related biases in treatment outcomes. Microneedling and fractional CO₂ laser demonstrated efficacy in stimulating epidermal alterations and facilitating melanocyte migration, offering promising outcomes for resistant vitiligo cases. Comparative studies emphasized the effectiveness of these treatments in enhancing repigmentation rates, suggesting the potential for innovative combination therapies to improve treatment outcomes for vitiligo patients.^{1,19,21,22,28}

The study discussed various important findings related to vitiligo treatment. Here are some key achievements highlighted in the text with reference numbers at the end of each sentence to create related and continuous sentences.

This study emphasizes the need for further research on the effectiveness of microneedling and fractional CO₂ laser in vitiligo treatment.

Study limitations, including sample size concerns for generalizability and challenges in maintaining blinding, were acknowledged. Further research with larger sample sizes and extended follow-up periods is recommended to validate these findings and explore potential relationships between treatment effectiveness and demographic variables.

Conclusion

In conclusion, combining NB-UVB and topical steroid therapies with the fractional CO₂ laser or microneedling seems to be effective for vitiligo treatment in resistant areas. Attention to variations in patients' characteristics and specific body locations is necessary when applying these modalities. This study provides valuable insights into novel approaches for managing vitiligo and highlights the potential benefits of these innovative treatments in combination with conventional therapy.

Acknowledgements

The authors express their heartfelt gratitude to the patients who generously supported this research. Their participation and commitment have been invaluable in advancing our understanding of vitiligo treatment. This study received valuable support from the Skin and Stem Cell Research Center of Tehran University of Medical Sciences.

Authors' Contribution

Conceptualization: Mohammadreza Rahbar, Parvin Mansouri.

Data curation: Mohammadreza Rahbar, Parvin Mansouri, Mohammad Ali Nilforoushzadeh,

Formal analysis: Mohammadreza Rahbar, Mohsen Shati.

Investigation: Mohammad Ali Nilforoushzadeh.

Methodology: Parvin Mansouri, Mohammadreza Rahbar, Mohammad Ali Nilforoushzadeh, Mohsen Shati, Mohammad Amir Amirkhani.

Project administration: Parvin Mansouri.

Supervision: Mohammad Ali Nilforoushzadeh, Mohammad Amir Amirkhani.

Validation: Mohammadreza Rahbar, Mohsen Shati.

Writing—original draft: Parvin Mansouri, Mohammadreza Rahbar, Mohammad Ali Nilforoushzadeh, Mohsen Shati.

Writing—review & editing: Mohammadreza Rahbar.

Competing Interests

The authors declared no conflicts of interest.

Ethical Approval

This study upholds ethical standards with informed consent, voluntary participation, and access to treatment upon withdrawal. Participants were briefed on potential benefits, side effects, and information confidentiality. All aspects, including interventions and assessments, were carefully anticipated. Participants with side effects were assessed by a dermatologist and, if necessary, directed to alternative treatments. Ethical approval has been obtained from the Ethical Committee of Tehran University of Medical Sciences with reference number IR.TUMS.VCR.REC.1395.152. The research has also been registered in the Iranian Registry of Clinical Trials (IRCT) with registration number: IRCT2016111630918N1 and Registration date: 2017-02-06.

Funding

None.

References

- Bergqvist C, Ezzedine K. Vitiligo: a review. *Dermatology*. 2020;236(6):571-92. doi: [10.1159/000506103](https://doi.org/10.1159/000506103).
- Massarrat MS, Tahaghoghi-Mehrizi S. Iranian national health survey: a brief report. *Arch Iran Med*. 2002;5(2):73-9.
- Hamidzadeh N, Ranjbar S, Ghanizadeh A, Parvizi MM, Jafari P, Handjani F. Evaluating prevalence of depression, anxiety and hopelessness in patients with vitiligo on an Iranian population. *Health Qual Life Outcomes*. 2020;18(1):20. doi: [10.1186/s12955-020-1278-7](https://doi.org/10.1186/s12955-020-1278-7).
- Ucuz I, Altunisik N, Sener S, Turkmen D, Kavuran NA, Marsak M, et al. Quality of life, emotion dysregulation, attention deficit and psychiatric comorbidity in children and adolescents with vitiligo. *Clin Exp Dermatol*. 2021;46(3):510-5. doi: [10.1111/ced.14196](https://doi.org/10.1111/ced.14196).
- Ongenaë K, Beelaert L, van Geel N, Naeyaert JM. Psychosocial effects of vitiligo. *J Eur Acad Dermatol Venereol*. 2006;20(1):1-8. doi: [10.1111/j.1468-3083.2005.01369.x](https://doi.org/10.1111/j.1468-3083.2005.01369.x).
- Bastonini E, Bellei B, Filoni A, Kovacs D, Iacovelli P, Picardo M. Involvement of non-melanocytic skin cells in vitiligo. *Exp Dermatol*. 2019;28(6):667-73. doi: [10.1111/exd.13868](https://doi.org/10.1111/exd.13868).
- Speeckaert R, van Geel N. Distribution patterns in generalized vitiligo. *J Eur Acad Dermatol Venereol*. 2014;28(6):755-62. doi: [10.1111/jdv.12171](https://doi.org/10.1111/jdv.12171).
- Mansouri P, Rahbar M, Nilforouszadeh MA, Shati M. Clinical profile and quality of life in patients with resistant to treatment vitiligo lesions in Iran: vitiligo patients need medico-psychosocial assistance. *Iran Red Crescent Med J*. 2023;25(9):e2626. doi: [10.32592/ircmj.2023.25.9.2626](https://doi.org/10.32592/ircmj.2023.25.9.2626).
- Nayak D, Vinay K, Dev A, Bishnoi A, Kumaran MS, Parsad D. Dermatoscopic evaluation of treatment response in patients undergoing NB-UVB phototherapy for the treatment of non-segmental vitiligo: a prospective study. *Photodermatol Photoimmunol Photomed*. 2023;39(3):279-81. doi: [10.1111/phpp.12825](https://doi.org/10.1111/phpp.12825).
- Mehta C, Mohammad T, Mehta D, Griffith J, Nicholson C, Hamzavi I. Effect of combination NSAID and NB-UVB treatment in non-photoadapters-a pilot study. *Photodermatol Photoimmunol Photomed*. 2019;35(5):318-21. doi: [10.1111/phpp.12476](https://doi.org/10.1111/phpp.12476).
- Eleftheriadou V. Phototherapy and lasers in the treatment of vitiligo. In: *Hypopigmentation*. CRC Press; 2019. p. 79-83.
- Karagaiah P, Valle Y, Sigova J, Zerbinati N, Vojvodic P, Parsad D, et al. Emerging drugs for the treatment of vitiligo. *Expert Opin Emerg Drugs*. 2020;25(1):7-24. doi: [10.1080/14728214.2020.1712358](https://doi.org/10.1080/14728214.2020.1712358).
- Silverberg N, Weingarten M, Desai S, Huang V, Walsh S, Rosmarin D. A review of the vitiligo literature to standardize the expression of disease severity. *Br J Dermatol*. 2023;188(Suppl 1):ljac106-008. doi: [10.1093/bjd/ljac106.008](https://doi.org/10.1093/bjd/ljac106.008).
- Sendrasoa FA, Ranaivo IM, Sata M, Andrianarison M, Raharolahy O, Rakotoarisaona MF, et al. Treatment responses in patients with vitiligo to very potent topical corticosteroids combined with vitaminotherapy in Madagascar. *Int J Dermatol*. 2019;58(8):908-11. doi: [10.1111/ijd.14510](https://doi.org/10.1111/ijd.14510).
- Kwon HB, Choi Y, Kim HJ, Lee AY. The therapeutic effects of a topical tretinoin and corticosteroid combination for vitiligo: a placebo-controlled, paired-comparison, left-right study. *J Drugs Dermatol*. 2013;12(4):e63-7.
- Whitton ME, Pinart M, Batchelor J, Leonardi-Bee J, González U, Jiyad Z, et al. Interventions for vitiligo. *Cochrane Database Syst Rev*. 2015;2015(2):CD003263. doi: [10.1002/14651858.CD003263.pub5](https://doi.org/10.1002/14651858.CD003263.pub5).
- Thi Thu Hien T, Doanh LH. Efficacy of the combination of fractional laser CO₂ and narrowband ultraviolet B in the treatment of non-segmental vitiligo. *Dermatology*. 2022(36):47-54.
- Mansouri P, Rahbar M, Nilforouszadeh MA, Shati M. Exploring the efficacy of fractional carbon dioxide laser as an add-on combination to conventional therapies for treatment-resistant vitiligo (a review article). *J Lasers Med Sci*. 2023;14:e51. doi: [10.34172/jlms.2023.51](https://doi.org/10.34172/jlms.2023.51).
- Olisova OY, Nikulina AS, Krotkova EA, Lazareva PI, Lomonosov KM. Possibilities of microneedling in the combined therapy of vitiligo. Literature review. *Russian Journal of Skin and Venereal Diseases*. 2022;25(5):363-71. doi: [10.17816/dv111066](https://doi.org/10.17816/dv111066).
- Esmat S, Assaf MI, Mohye Eldeen R, Gawdat HI, Saadi DG. Evaluation of needling/microneedling as an adjunct to phototherapy in the treatment of stable acral vitiligo: a comparative clinical and immunohistochemical study. *J Dermatolog Treat*. 2022;33(5):2621-8. doi: [10.1080/09546634.2022.2062279](https://doi.org/10.1080/09546634.2022.2062279).
- Salloom A, Bazzi N, Maalouf D, Habre M. Microneedling in vitiligo: a systematic review. *Dermatol Ther*. 2020;33(6):e14297. doi: [10.1111/dth.14297](https://doi.org/10.1111/dth.14297).
- Afiy AA, Zuelfakkar NM, Eshafi MA. Fractional CO₂ laser, platelet rich plasma and narrow band ultraviolet B in the treatment of vitiligo (a randomized clinical trial). *Lasers Med Sci*. 2021;36(7):1479-86. doi: [10.1007/s10103-020-03195-9](https://doi.org/10.1007/s10103-020-03195-9).
- Abu Zeid OM, Omar N, El Sharkawy D. The efficacy of combining fractional CO₂ laser and tacrolimus ointment in the treatment of vitiligo. *J Egypt Womens Dermatol Soc*. 2020;17(1):25-30. doi: [10.4103/jewd.jewd_41_19](https://doi.org/10.4103/jewd.jewd_41_19).
- Cunha PR, Scabine Pessotti N, Bonati Mattos C, Salai AF. New approach in the treatment of refractory vitiligo: CO₂ laser combined with betamethasone and salicylic acid solution. *Dermatol Ther*. 2017;30(1):e12410. doi: [10.1111/dth.12410](https://doi.org/10.1111/dth.12410).
- Basak PY, Adiloglu AK, Ceyhan AM, Tas T, Akkaya VB. The role of helper and regulatory T cells in the pathogenesis of vitiligo. *J Am Acad Dermatol*. 2009;60(2):256-60. doi: [10.1016/j.jaad.2008.09.048](https://doi.org/10.1016/j.jaad.2008.09.048).
- Narayan VS, Uitentuis SE, Luiten RM, Bekkenk MW, Wolkerstorfer A. Patients' perspective on current treatments and demand for novel treatments in vitiligo. *J Eur Acad Dermatol Venereol*. 2021;35(3):744-8. doi: [10.1111/jdv.16927](https://doi.org/10.1111/jdv.16927).
- Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY. DLQI scores in vitiligo: reliability and validity of the Persian version. *BMC Dermatol*. 2004;4:8. doi: [10.1186/1471-5945-4-8](https://doi.org/10.1186/1471-5945-4-8).
- Anbar TS, Westerhof W, Abdel-Rahman AT, El-Khayyat MA. Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites. *Photodermatol Photoimmunol Photomed*. 2006;22(3):157-63. doi: [10.1111/j.1600-0781.2006.00222.x](https://doi.org/10.1111/j.1600-0781.2006.00222.x).